IBM Sells Off Watson Health Assets

Jan. 21, 2022
Investment firm Francisco Partners buying Health Insights, MarketScan, Clinical Development, Social Program Management, Micromedex, and imaging software offerings

IBM has agreed to sell healthcare data and analytics assets that are part of its Watson Health business to investment firm Francisco Partners for an undisclosed sum.

The Armonk, N.Y.-based company said the assets acquired by Francisco Partners include extensive and diverse data sets and products, including Health Insights, MarketScan, Clinical Development, Social Program Management, Micromedex, and imaging software offerings.

As Axios first reported on Jan. 5, IBM (NYSE: IBM) initially explored putting IBM Watson Health up for sale in early 2021, seeking approximately $1 billion, and in late 2021 engaged BofA Securities to find a buyer. IBM had built the business in part through acquisitions such as Truven Health Analytics, Phytel, and medical imaging company Merge Healthcare.

“Today’s agreement with Francisco Partners is a clear next step as IBM becomes even more focused on our platform-based hybrid cloud and AI strategy,” said Tom Rosamilia, senior vice president of IBM Software, in a statement. “IBM remains committed to Watson, our broader AI business, and to the clients and partners we support in healthcare IT. Through this transaction, Francisco Partners acquires data and analytics assets that will benefit from the enhanced investment and expertise of a healthcare industry-focused portfolio.”

San Francisco-based Francisco Partners has made previous investments in healthcare technology. Some current and past investments in the sector include Availity, eSolutions, Capsule, GoodRx, Landmark, QGenda, Trellis, and Zocdoc.

Noting that they have experience in such divisional carve-outs, Francisco executives said the current management team will continue in similar roles in a new stand-alone company, serving existing clients in life sciences, provider, imaging, payer and employer, and government health and human services sectors.

“We have followed IBM’s journey in healthcare data and analytics for a number of years and have a deep appreciation for its portfolio of innovative healthcare products,” said Ezra Perlman, co-president at Francisco Partners, in a statement. “IBM built a market leading team and provides its customers with mission critical products and outstanding service.”

The transaction is expected to close in the second quarter of this year. IBM will announce its fourth-quarter 2021 earnings on Jan. 24, 2022.

Sponsored Recommendations

Patient Engagement and ML/AI – Modern Interoperability as an enabler for value based care

Discover how modern interoperability empowers patient engagement and leverages ML/AI for better outcomes in value-based care. Join us on June 18th to learn how seamless data integration...

The Crushing Weight of Healthcare Cloud Compliance & Security Debt: Perspectives & Strategies

Discover how to navigate the pressing challenges of healthcare cloud compliance and security. Join industry experts as they unveil key insights and actionable strategies to break...

Telehealth: Moving Forward Into the Future

Register now to explore two insightful sessions that delve into the transformative potential of telehealth and virtual care management solutions.

Telehealth: Moving Forward Into the Future

Register now to explore two insightful sessions that delve into the transformative potential of telehealth and virtual care management solutions.